Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIT-2 trial of capecitabine versus capecitabine plus mitomycin C in second-line advanced biliary tract cancer
2011-002002-70Phase 2Terminated
- Sponsor
- Fondazione Centro San Raffaele
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, mitomycin c in biliary adenocarcinoma, gallbladder adenocarcinoma, ampullary adenocarcinoma, cholangiocarcinoma (CCA), sponsored by Fondazione Centro San Raffaele. Started Jan 2012; status: terminated.
02
Drugs
capecitabinemitomycin c
03
Conditions
biliary adenocarcinomagallbladder adenocarcinomaampullary adenocarcinomacholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2011-002002-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002002-70.